European Cancer Congress 2017

login
My congress planner

ESO

ESO

ECCO2017 ESO Society Day

register now

Breast Cancer Screening and Early Detection

27 January 2017, Amsterdam, The Netherlands

Chairs:  F. Cardoso, PT - C. de Wolf, CH - J. Geraghty, IE

INTRODUCTION

Tomosynthesis carries a great promise in improving cancer detection and reducing the number of false positives. As yet its drawbacks are: higher and longer radiation exposure, longer compression time and therefore longer lasting pain and longer interpretation time.  However, is there a role for tomosynthesis in screening?

This conference topic will address many elements.  Is tomosynthesis the better screening mammogram? Does DBT reduce interval cancers?  What are the technical hurdles (compatibility, data volumes) to use DBT in screening? How to compare with previous mammograms?  Is DBT screening cost effective? What are the views of screening programs and the European Commission? 

Is there a future for “Risk based screening”?   There is a variable breast cancer risk in the population.

You can think of familial risk factors, genetic risk factors, breast density but also age.  Often some of these subgroups are excluded from screening or need additional imaging.  Is it possible for a screening program to offer personalized services for high risk groups and how can we calculate the risk level?

PROGRAMME

09.00-10.30

BREAST SCREENING PROGRAMMES & POLICIES
Chair: Fatima Cardoso (PT)

09.00-09.10

Introductory remarks
C. De Wolf (CH)

09.10-09.30

Understanding differences in screening effect from observational studies
S. Duffy (UK)

09.30-09.50

Health economics in screening
C. Normand (IE)

09.50-10.10

Informed decision-making for women - Is it possible?
M. Solbjor (NO)

10.10-10.30

Discussion

10.30-11.00

Coffee break

 

11.00-12.30

IS TOMOSYNTHESIS READY FOR PRIME TIME?
Chair: Chris de Wolf (CH)

11.00-11.20

Adding tomosynthesis to mammography for population screening
S. Hofvind (NO)

11.20-11.40

Tomosynthesis-only compared to conventional screening
S. Heywang (DE)

11.40-12.00

Decision models on tomosynthesis in the Netherlands
N. de Jong (NL)

12.00-12.20

Medical, legal and ethical implications of tomosynthesis in screening
E.B. van Veen (NL)

12.20-12.40

Discussion

12.40-14.00

Lunch

 

14.00-15.30 

RISK-BASED SCREENING
Chair: James Geraghty (IE)

14.00-14.20

Eu-topia Towards improved screening in All of Europe
H. de Koning (NL)

14.20-14.40

Conceptual issues regarding risk based screening
M. Broeders (NL)

14.40-15.00

Screening and chemoprevention: The way forward?
A. De Censi (IT)                                              

15.00-15.30

Discussion

15.30-16.00

Coffee break

 

16.00-17.30 

HOT TOPICS IN BREAST SCREENING
Chair: Fedro Peccatori (IT)

16.00-16.20

Should breast screening be mandatory?
B. Borisch (CH)

16.20-16.40 

Breast screening in Europe and new European breast guidelines
C. De Wolf (CH)

16.40-17.00

Breast screening in 2025: A challenging forecast (neural network
diagnosis)
S. Zackrisson (SE)

17.00-17.20 

Discussion

17.20-17.30 

Closing remarks

PRINT THIS PAGE Page last modified: